澳博达文献集8.pdfVIP

$162 A b s t r a c t s J ALLERGY CLIN IMMUNOL JANUARY 2002 76CombinationTreatment With Cetirizine and Zafirlukast with treatment duration of 14 (2 studies) or 28 days (1 study), in children Improves Urticaria in Patients With Autoantibody to FcEI with allergic conjunctivitis. Efficacy of AZE was evaluated by severity Receptors scores for both itching and redness of the eyes assessed by blinded investi- Jonathan A Bernstein, Linda Levin, Wei Zhong University of Cincinnati, gators at days 0, 3, and 14 of treatment. Severity for each symptom was Cincinnati, OH assessed separately on a 4 point scale ranging from 0 (no itching or redness) Since leukotrienes (LT) have potent effects on skin vasculature, LT modi- to 3 (severe itching or redness). Redness improved in all three studies for fying agents (LTMA) may be effective for treatment of chronic urticaria both the AZE and PLA groups at day 3 and at day 14, but the extent of (CU). A double-blind, placebo-controlled trial of cetirizine (C) 10 mg qhs improvement in severity scores was consistently greater in the AZE group. and zafirlukast (Z) 20 mg bid vs. C 10mg qhs and placebo (P) was conducted Similarly, improvement in ocular itching was greater in the AZE vs. PLA to determine if patients (pts) with CU benefit from add-on therapy with a group, especially at day 3 (see Table).